Factors associated with the development of brain metastases

Cancer

Volumn 116, Issue 21, 2010, Pages 5038-5046

  Hubbs, Jessica L ^a   Boyd, Jessamy A ^b   Hollis, Donna ^c   Chino, Junzo P ^b   Saynak, Mert ^d   Kelsey, Chris R ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d TRAKYA UNIVERSITY   (Turkey)

Author keywords

Brain metastases; Nonsmall cell lung cancer; Patterns of failure; Prophylactic cranial irradiation

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER INVASION; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; GROUPS BY AGE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; LYMPH NODE; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RISK FACTOR; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CRANIAL IRRADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 78249232963     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25254     Document Type: Article

References (63)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71 -96.
2. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN Jr., Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008; 168: 1541 -1549.
3. Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7: 719 -727.
4. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer [abstract]. N Engl J Med. 2005; 352: 2589 -2597.
5. Strauss GM, Herndon JE,. 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008; 26: 5043 -5051.
6. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352: 2589 -2597.
7. Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A,. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94: 2698 -2705. http://dx.doi.org/10.1002/ cncr.10541.
8. Sorensen JB, Hansen HH, Hansen M, Dombernowsky P,. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988; 6: 1474 -1480.
9. Newman SJ, Hansen HH., Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974; 33: 492 -496.
10. Komaki R, Cox JD, Stark R., Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival. Int J Radiat Oncol Biol Phys. 1983; 9: 1467 -1470.
11. Cox JD, Yesner RA., Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. Am Rev Respir Dis. 1979; 120: 1025 -1029.
12. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995; 109: 120 -129.
13. Komaki R, Scott CB, Byhardt R, et al. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on 4 radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1998; 42: 263 -267.
14. Cox JD, Scott CB, Byhardt RW, et al. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 1999; 43: 505 -509.
15. AJCC. Cancer Staging Handbook, 6th ed. New York: Springer; 2002.
16. Collett D., Modeling Survival Data in Medical Research, 2nd ed. London: Chapman & Hall; 2003.
17. Therneau TM, Grambsch PM., Modeling Survival Data. New York: Springer; 2000.
18. Ginsberg RJ, Rubinstein LV., Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60: 615 -623; discussion 622-623.
19. Lafitte JJ, Ribet ME, Prevost BM, Gosselin BH, Copin MC, Brichet AH., Postresection irradiation for T2 N0 M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg. 1996; 62: 830 -834.
20. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol. 2002; 62: 11 -19.
21. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys. 1980; 6: 983 -986.
22. Feld R, Rubinstein LV, Weisenberger TH., Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol. 1984; 2: 1352 -1358.
23. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350: 1713 -1721.
24. Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB., Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005; 80: 268 -274; discussion 274-275.
25. Harpole DH Jr, Herndon JE, 2nd, Young WG Jr, Wolfe WG, Sabiston DC Jr,. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76: 787 -796.
26. Immerman SC, Vanecko RM, Fry WA, Head LR, Shields TW., Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg. 1981; 32: 23 -27.
27. Sawyer TE, Bonner JA, Gould PM, et al. Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma. Ann Thorac Surg. 1999; 68: 1171 -116.
28. Luzzi L, Voltolini L, Campione A, et al. Pneumonectomy versus lobectomy in the treatment of pathologic N1 NSCLC: could the type of surgical resection dictate survival? J Cardiovasc Surg (Torino). 2003; 44: 119 -123.
29. Kim YT, Kang CH, Sung SW, Kim JH., Local control of disease related to lymph node involvement in non-small cell lung cancer after sleeve lobectomy compared with pneumonectomy. Ann Thorac Surg. 2005; 79: 1153 -1161; discussion 1153-1161.
30. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2000; 47: 925 -929.
31. Ceresoli GL, Reni M, Chiesa G, et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment. Cancer. 2002; 95: 605 -612.
32. Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM., Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol. 2001; 19: 1344 -1349.
33. Mamon HJ, Yeap BY, Janne PA, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005; 23: 1530 -157.
34. Chen AM, Jahan TM, Jablons DM, Garcia J, Larson DA., Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 2007; 109: 1668 -1675.
35. Carolan H, Sun AY, Bezjak A, et al. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer 2005; 49: 109 -115.
36. Bajard A, Westeel V, Dubiez A, et al. Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer. 2004; 45: 317 -323.
37. Tang SG, Tseng CK, Tsay PK, et al. Predictors for patterns of brain relapse and overall survival in patients with non-small cell lung cancer. J Neurooncol. 2005; 73: 153 -161.
38. Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007; 242: 882 -888.
39. Figlin RA, Piantadosi S, Feld R,. Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. N Engl J Med. 1988; 318: 1300 -1305.
40. Rena O, Oliaro A, Cavallo A, et al. Stage I non-small cell lung carcinoma: really an early stage? Eur J Cardiothorac Surg. 2002; 21: 514 -519.
41. Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg. 2001; 19: 555 -561.
42. Fu XL, Zhu XZ, Shi DR, et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer. 1999; 23: 143 -152.
43. Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses Cancer. 1999; 86: 1976 -1984.
44. Rigau V, Molina TJ, Chaffaud C, et al. Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence. Lung Cancer. 2002; 38: 169 -176.
45. Tsuchiya T, Akamine S, Muraoka M, et al. Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer. 2007; 56: 341 -348.
46. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005; 23: 2955 -2961.
47. D'Amico TA, Aloia TA, Moore MB, et al. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg. 2001; 72: 1144 -118.
48. Saad AG, Yeap BY, Thunnissen FB, et al. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer. 2008; 113: 2129 -2138.
49. Anguiano A, Nevins JR, Potti A,. Toward the individualization of lung cancer therapy. Cancer. 2008; 113 (7 suppl): 1760 -1767. http://dx.doi.org/10. 1002/cncr.23644.
50. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006; 355: 570 -580.
51. Chen HY, Yu SL, Chen CH, et al. A 5-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007; 356: 11 -20.
52. Grinberg, Rashi H, Ofek E, Perelman M, et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res. 2009: 15: 1755 -1761.
53. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999; 341: 476 -484.
54. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357: 664 -672.
55. Umsawasdi T, Valdivieso M, Chen TT, et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol. 1984; 2: 253 -259.
56. Russell AH, Pajak TE, Selim HM, et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1991; 21: 637 -643.
57. Pottgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol. 2007; 25: 4987 -4992.
58. Figlin, RA, Piantadosi S, Feld R,. Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. N Engl J Med. 1988; 318: 1300 -135.
59. The Ludwig Lung Cancer Study Group. Patterns of failure in patients with resected stage I and II non-small-cell carcinoma of the lung. Ann Surg. 1987; 205: 67 -71.
60. Gilbert S, Reid KR, Lam MY, Petsikas D., Who should follow up lung cancer patients after operation? Ann Thorac Surg. 2000; 69: 1696 -1700.
61. Matsuoka K, Sumitomo S, Misaki N., Prognostic factors in patients with pathologic T1-2N1M0 disease in non-small cell carcinoma of the lung. J Thorac Oncol. 2007; 2: 1098 -1102.
62. Movsas B, Bae K, Meyers C, Gore E, Bonner J, Sun A, et al. Phase III study of prophylactic cranial irradiation vs. observation in patients with stage III non-small-cell lung cancer: neurocognitive and quality of life analysis of RTOG 0214. Proceedings of ASTRO. 2009; 75: S1.
63. Law A, Karp DD, Dipetrillo T, Daly BT., Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer. 2001; 92: 160 -164.